Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
War in Ukraine: Global cancer aid to support refugees
Dr Horia Vulpe , Dr Ruslan Baltaga
War in Ukraine: Global cancer aid to support refugees ( Dr Horia Vulpe , Dr Ruslan Baltaga )
21 Jun 2022
War in Ukraine: The International Brain Tumour Alliance's response to aiding ref...
Kathy Oliver- Chair and Co-Director, International Brain Tumour Alliance
War in Ukraine: The International Brain Tumour Alliance's response to aiding refugees during the crisis ( Kathy Oliver- Chair and Co-Director, International Brain Tumour Alliance )
21 Jun 2022
Ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukaemia...
Dr Carol Moreno - University of Barcelona, Barcelona, Spain
Ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL) ( Dr Carol Moreno - University of Barcelona, Barcelona, Spain )
21 Jun 2022
Rucaparib effective as maintenance therapy following first-line platinum-based c...
Dr Bradley Monk - University of Arizona College, Tucson, USA
Rucaparib effective as maintenance therapy following first-line platinum-based chemo in ovarian cancer ( Dr Bradley Monk - University of Arizona College, Tucson, USA )
21 Jun 2022
RAGNAR study evidences efficacy and safety of erdafitinib in patients with advan...
Dr Yohann Loriot - Institut Gustave Roussy, Villejuif, France
RAGNAR study evidences efficacy and safety of erdafitinib in patients with advanced FGFR+ malignancies ( Dr Yohann Loriot - Institut Gustave Roussy, Villejuif, France )
17 Jun 2022
ASCO 2022: The latest in RCC
Prof James Larkin, Dr Bernard Escudier, Prof Jens Bedke and Dr Toni Choueiri
ASCO 2022: The latest in RCC ( Prof James Larkin, Dr Bernard Escudier, Prof Jens Bedke and Dr Toni Choueiri )
17 Jun 2022
ASCO and WHO to collaborate on quality indicators for cancer facilities
Dr André Ilbawi - WHO Headquarters, Geneva, Switzerland
ASCO and WHO to collaborate on quality indicators for cancer facilities ( Dr André Ilbawi - WHO Headquarters, Geneva, Switzerland )
14 Jun 2022
Efficacy and safety of ARI0002H, a BCMA-directed CAR-T cell therapy with fractio...
Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Spain
Efficacy and safety of ARI0002H, a BCMA-directed CAR-T cell therapy with fractionated initial therapy and booster dose in RRMM ( Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Spain )
14 Jun 2022
R-CODOX-M/R-IVAC versus dose-adjusted-EPOCH-R in patients with newly diagnosed h...
Dr Martine Chamuleau - Amsterdam UMC, Amsterdam, Netherlands
R-CODOX-M/R-IVAC versus dose-adjusted-EPOCH-R in patients with newly diagnosed high-risk lymphoma ( Dr Martine Chamuleau - Amsterdam UMC, Amsterdam, Netherlands )
14 Jun 2022
Comment: Addition of ixazomib to pomalidomide and dexamethasone improves surviva...
Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA
Comment: Addition of ixazomib to pomalidomide and dexamethasone improves survival for multiple myeloma patients ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )
14 Jun 2022
EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDM...
Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA
EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )
14 Jun 2022
Safety and efficacy of the bispecific antibody talquetamab in relapsed/refractor...
Prof Monique Minnema - University Medical Center Utrecht, Utrecht, Netherlands
Safety and efficacy of the bispecific antibody talquetamab in relapsed/refractory multiple myeloma ( Prof Monique Minnema - University Medical Center Utrecht, Utrecht, Netherlands )
13 Jun 2022